BlinkLab (ASX: BB1) has announced the completion of its clinical site network for a pivotal FDA 510(k) study, a critical step towards potential clearance of its BlinkLab Dx 1 device.
This, coupled with strong pilot data, signals significant progress in the company's regulatory pathway.
The company has officially onboarded 10 clinical sites across the US for the study, with the University of Arkansas the final site to be included in this comprehensive network.
First patient testing in this pivotal trial is expected to commence by the end of March 2026.
The study is designed to enroll a minimum of 528 children aged between two and 11 years.
Strong Pilot Data Supports FDA Pathway
A U.S. pilot study involving 485 children demonstrated robust diagnostic performance for the BlinkLab Dx 1 device.
Pilot results of 83.7% sensitivity and **84.7% specificity **comfortably exceed the FDA's stated thresholds of 65% for both metrics, providing a strong foundation for the upcoming pivotal study and strengthening the company's regulatory credibility.
The completion of the clinical site network marks a crucial milestone for initiating the pivotal FDA study, a development that aligns with the company's goal of achieving regulatory clearance for BlinkLab Dx 1.
BlinkLab is targeting a 510(k) submission in the second half of CY2026.
The company's technology has previously received independent validation, including a peer-reviewed publication in Autism Research in January 2026, further strengthening its regulatory pathway.
Financial Health and Runway
BlinkLab reported a net loss of A$3,762,532 for the half-year ended 31 December 2025, with revenue remaining flat at A$160,598.
This reflects the company's ongoing investment in research and development and regulatory activities.
As of December 2025, cash and cash equivalents stood at A$5,509,160, providing an estimated 12-month funding runway.
Post-period, BlinkLab announced an R&D tax incentive refund of A$822,205 and issued 1,400,000 performance rights related to FDA approval milestones.
Outlook for BlinkLab
With its clinical site network established and strong pilot data, BlinkLab is poised to commence its pivotal FDA study, a crucial step for potential market clearance.
However, the company continues to operate at a loss and will rely on its current cash reserves and potentially future funding to navigate regulatory and commercialisation challenges.
